Literature DB >> 7798324

Bone morphogenetic protein-2 converts the differentiation pathway of C2C12 myoblasts into the osteoblast lineage.

T Katagiri1, A Yamaguchi, M Komaki, E Abe, N Takahashi, T Ikeda, V Rosen, J M Wozney, A Fujisawa-Sehara, T Suda.   

Abstract

The implantation of bone morphogenetic protein (BMP) into muscular tissues induces ectopic bone formation at the site of implantation. To investigate the mechanism underlying this process, we examined whether recombinant bone morphogenetic protein-2 (BMP-2) converts the differentiation pathway of the clonal myoblastic cell line, C2C12, into that of osteoblast lineage. Incubating the cells with 300 ng/ml of BMP-2 for 6 d almost completely inhibited the formation of the multinucleated myotubes expressing troponin T and myosin heavy chain, and induced the appearance of numerous alkaline phosphatase (ALP)-positive cells. BMP-2 dose dependently induced ALP activity, parathyroid hormone (PTH)-dependent 3',5'-cAMP production, and osteocalcin production at concentrations above 100 ng/ml. The concentration of BMP-2 required to induce these osteoblastic phenotypes was the same as that required to almost completely inhibit myotube formation. Incubating primary muscle cells with 300 ng/ml of BMP-2 for 6 d also inhibited myotube formation, whereas induced ALP activity and osteocalcin production. Incubation with 300 ng/ml of BMP-2 suppressed the expression of mRNA for muscle creatine kinase within 6 h, whereas it induced mRNA expression for ALP, PTH/PTH-related protein (PTHrP) receptors, and osteocalcin within 24-48 h. BMP-2 completely inhibited the expression of myogenin mRNA by day 3. By day 3, BMP-2 also inhibited the expression of MyoD mRNA, but it was transiently stimulated 12 h after exposure to BMP-2. Expression of Id-1 mRNA was greatly stimulated by BMP-2. When C2C12 cells pretreated with BMP-2 for 6 d were transferred to a colony assay system in the absence of BMP-2, more than 84% of the colonies generated became troponin T-positive and ALP activity disappeared. TGF-beta 1 also inhibited myotube formation in C2C12 cells, and suppressed the expression of myogenin and MyoD mRNAs without inducing that of Id-1 mRNA. However, no osteoblastic phenotype was induced by TGF-beta 1 in C2C12 cells. TGF-beta 1 potentiated the inhibitory effect of BMP-2 on myotube formation, whereas TGF-beta 1 reduced ALP activity and osteocalcin production induced by BMP-2 in C2C12 cells. These results indicate that BMP-2 specifically converts the differentiation pathway of C2C12 myoblasts into that of osteoblast lineage cells, but that the conversion is not heritable.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7798324      PMCID: PMC2120318          DOI: 10.1083/jcb.127.6.1755

Source DB:  PubMed          Journal:  J Cell Biol        ISSN: 0021-9525            Impact factor:   10.539


  84 in total

1.  Type beta transforming growth factor is an inhibitor of myogenic differentiation.

Authors:  J Massagué; S Cheifetz; T Endo; B Nadal-Ginard
Journal:  Proc Natl Acad Sci U S A       Date:  1986-11       Impact factor: 11.205

2.  Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction.

Authors:  P Chomczynski; N Sacchi
Journal:  Anal Biochem       Date:  1987-04       Impact factor: 3.365

3.  Transforming growth factor-beta modulates the expression of osteoblast and chondroblast phenotypes in vitro.

Authors:  D M Rosen; S A Stempien; A Y Thompson; S M Seyedin
Journal:  J Cell Physiol       Date:  1988-03       Impact factor: 6.384

4.  Isolation of osteogenin, an extracellular matrix-associated, bone-inductive protein, by heparin affinity chromatography.

Authors:  T K Sampath; N Muthukumaran; A H Reddi
Journal:  Proc Natl Acad Sci U S A       Date:  1987-10       Impact factor: 11.205

5.  Inhibition of myogenic differentiation by fibroblast growth factor or type beta transforming growth factor does not require persistent c-myc expression.

Authors:  G Spizz; J S Hu; E N Olson
Journal:  Dev Biol       Date:  1987-10       Impact factor: 3.582

6.  Type-beta transforming growth factor inhibits proliferation and expression of alkaline phosphatase in murine osteoblast-like cells.

Authors:  M Noda; G A Rodan
Journal:  Biochem Biophys Res Commun       Date:  1986-10-15       Impact factor: 3.575

7.  Expression of multiple troponin T variants in neonatal chicken breast muscle.

Authors:  H Abe; T Komiya; T Obinata
Journal:  Dev Biol       Date:  1986-11       Impact factor: 3.582

8.  Expression of a single transfected cDNA converts fibroblasts to myoblasts.

Authors:  R L Davis; H Weintraub; A B Lassar
Journal:  Cell       Date:  1987-12-24       Impact factor: 41.582

9.  Transforming growth factor-beta. A very potent inhibitor of myoblast differentiation, identical to the differentiation inhibitor secreted by Buffalo rat liver cells.

Authors:  J R Florini; A B Roberts; D Z Ewton; S L Falen; K C Flanders; M B Sporn
Journal:  J Biol Chem       Date:  1986-12-15       Impact factor: 5.157

10.  Growth factor control of skeletal muscle differentiation: commitment to terminal differentiation occurs in G1 phase and is repressed by fibroblast growth factor.

Authors:  C H Clegg; T A Linkhart; B B Olwin; S D Hauschka
Journal:  J Cell Biol       Date:  1987-08       Impact factor: 10.539

View more
  364 in total

1.  Ski represses bone morphogenic protein signaling in Xenopus and mammalian cells.

Authors:  W Wang; F V Mariani; R M Harland; K Luo
Journal:  Proc Natl Acad Sci U S A       Date:  2000-12-19       Impact factor: 11.205

2.  Finding genes in the C2C12 osteogenic pathway by k-nearest-neighbor classification of expression data.

Authors:  Joachim Theilhaber; Timothy Connolly; Sergio Roman-Roman; Steven Bushnell; Amanda Jackson; Kathy Call; Teresa Garcia; Roland Baron
Journal:  Genome Res       Date:  2002-01       Impact factor: 9.043

3.  BMP3 suppresses osteoblast differentiation of bone marrow stromal cells via interaction with Acvr2b.

Authors:  Shoichiro Kokabu; Laura Gamer; Karen Cox; Jonathan Lowery; Kunikazu Tsuji; Regina Raz; Aris Economides; Takenobu Katagiri; Vicki Rosen
Journal:  Mol Endocrinol       Date:  2011-11-10

4.  Wnt/β-catenin signaling activates bone morphogenetic protein 2 expression in osteoblasts.

Authors:  Rongrong Zhang; Babatunde O Oyajobi; Stephen E Harris; Di Chen; Christopher Tsao; Hong-Wen Deng; Ming Zhao
Journal:  Bone       Date:  2012-09-29       Impact factor: 4.398

5.  Serine phosphorylation of RUNX2 with novel potential functions as negative regulatory mechanisms.

Authors:  Hee-Jun Wee; Gang Huang; Katsuya Shigesada; Yoshiaki Ito
Journal:  EMBO Rep       Date:  2002-09-13       Impact factor: 8.807

6.  A novel regulatory mechanism of the bone morphogenetic protein (BMP) signaling pathway involving the carboxyl-terminal tail domain of BMP type II receptor.

Authors:  Mun Chun Chan; Peter H Nguyen; Brandi N Davis; Nobumichi Ohoka; Hidetoshi Hayashi; Keyong Du; Giorgio Lagna; Akiko Hata
Journal:  Mol Cell Biol       Date:  2007-06-18       Impact factor: 4.272

7.  Histone deacetylase 7 associates with Runx2 and represses its activity during osteoblast maturation in a deacetylation-independent manner.

Authors:  Eric D Jensen; Tania M Schroeder; Jaclyn Bailey; Rajaram Gopalakrishnan; Jennifer J Westendorf
Journal:  J Bone Miner Res       Date:  2008-03       Impact factor: 6.741

8.  Mammalian cell survival and processing in supercritical CO(2).

Authors:  Patrick J Ginty; Daniel Howard; Felicity R A J Rose; Martin J Whitaker; John J A Barry; Patrick Tighe; Stacey R Mutch; Gulay Serhatkulu; Richard O C Oreffo; Steven M Howdle; Kevin M Shakesheff
Journal:  Proc Natl Acad Sci U S A       Date:  2006-05-01       Impact factor: 11.205

9.  Myostatin signals through a transforming growth factor beta-like signaling pathway to block adipogenesis.

Authors:  A Rebbapragada; H Benchabane; J L Wrana; A J Celeste; L Attisano
Journal:  Mol Cell Biol       Date:  2003-10       Impact factor: 4.272

10.  p38 MAP kinase signalling is required for hypertrophic chondrocyte differentiation.

Authors:  Lee-Anne Stanton; Shalev Sabari; Arthur V Sampaio; T Michael Underhill; Frank Beier
Journal:  Biochem J       Date:  2004-02-15       Impact factor: 3.857

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.